Bin Wan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Bin Wan has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Haixia Ding
School of Pharmacy, Nanjing Medical University, Nanjing, Jiangsu, China
1 shared publication - Mengdie Zhang
School of Pharmacy, Nanjing Medical University, Nanjing, China
1 shared publication - Pengfei Wu
Pancreas Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
1 shared publication - Xin Li
Department of Clinical Pharmacy, School of Pharmacy, Nanjing Medical University, Nanjing, China
1 shared publication - Yingpeng Wang
Department of Health Insurance Management, The First Affiliated Hospital with Nanjing Medical University (Jiangsu Province Hospital), Nanjing, China
1 shared publication - Yuwen Bao
School of Health Policy and Management, Nanjing Medical University, Nanjing, China
1 shared publication
Latest Publications
- 19 September 2023
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 149 (18) , 1-11
Cost-effectiveness of open pancreaticoduodenectomy with or without Heidelberg TRIANGLE operation for pancreatic cancer in China
Objective Pancreatic cancer is a digestive malignancy with dismal prognosis. The advent of Heidelberg TRIANGLE dissection technique brings a turning point to improve the chance of survival. Our study aimed to evaluated the cost-effectiveness of open pancreaticoduodenectomy (OPD) versus OPD combined with TRIANGLE operation (OPD-TRIANGLE) for patients with pancreatic cancer from the perspective of healthcare system in China. Methods Two hundred forty-six patients with pancreatic cancer who underwent OPD or OPD-TRIANGLE from January to September 2022 were enrolled in this study. We performed a decision tree model to assess clinical and economic implications of different surgical strategies. Estimation of health utilities was based on published literature, while costs were acquired from the hospitals, clinical expert consultations, and other local charge. The incremental cost-effectiveness ratio (ICER) was regarded as the primary outcome. Uncertainty of the findings was addressed via sensitivity analyses and scenario analyses. Results The results indicated that OPD-TRIANGLE group yielded additional 0.0402 QALYs at an incremental cost of US$1501.83 compared with OPD group, and the corresponding ICER was US$37,358.96 per QALY. The probabilities of OPD-TRIANGLE as the prior option were 52.8% at the WTP threshold of 60,000 US$/QALY. The main factors lined with costs incorporating total medical costs and operation-related costs. With 5–20% price reduction of OPD-TRIANGLE, the outcomes were also economically attractive. Conclusion The findings of this population-based study suggested that OPD-TRIANGLE was likely to be cost-effective for patients with pancreatic cancer when compared against OPD. Further in-depth studies should be conducted to provide more comprehensive evidence.
- 19 September 2023
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 149 (18) , 1-11
Cost-effectiveness of open pancreaticoduodenectomy with or without Heidelberg TRIANGLE operation for pancreatic cancer in China
Objective Pancreatic cancer is a digestive malignancy with dismal prognosis. The advent of Heidelberg TRIANGLE dissection technique brings a turning point to improve the chance of survival. Our study aimed to evaluated the cost-effectiveness of open pancreaticoduodenectomy (OPD) versus OPD combined with TRIANGLE operation (OPD-TRIANGLE) for patients with pancreatic cancer from the perspective of healthcare system in China. Methods Two hundred forty-six patients with pancreatic cancer who underwent OPD or OPD-TRIANGLE from January to September 2022 were enrolled in this study. We performed a decision tree model to assess clinical and economic implications of different surgical strategies. Estimation of health utilities was based on published literature, while costs were acquired from the hospitals, clinical expert consultations, and other local charge. The incremental cost-effectiveness ratio (ICER) was regarded as the primary outcome. Uncertainty of the findings was addressed via sensitivity analyses and scenario analyses. Results The results indicated that OPD-TRIANGLE group yielded additional 0.0402 QALYs at an incremental cost of US$1501.83 compared with OPD group, and the corresponding ICER was US$37,358.96 per QALY. The probabilities of OPD-TRIANGLE as the prior option were 52.8% at the WTP threshold of 60,000 US$/QALY. The main factors lined with costs incorporating total medical costs and operation-related costs. With 5–20% price reduction of OPD-TRIANGLE, the outcomes were also economically attractive. Conclusion The findings of this population-based study suggested that OPD-TRIANGLE was likely to be cost-effective for patients with pancreatic cancer when compared against OPD. Further in-depth studies should be conducted to provide more comprehensive evidence.